Featured Event:
ChinaBio® Partnering Forum 2022
Beijing and Digital
September 13–16, 2022
 
ChinaBio® Partnering Forum is the largest and most productive life science partnering event in China. To be held as a 4-day hybrid event; 2 days in-person, 2 days virtually,September 13–16, 2022, the conference will bring together biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for four days of successful partnering. ChinaBio® Partnering Forum 2021 attracted 1,000+ delegates from over 500 companies and 27 countries, making it a must-attend global event for companies interested in developing cross-border partnerships, both inside and outside of China. In addition to partnering meetings, the event will feature a blend of live and on-demand program sessions, company presentations, table-top exhibits, company showcases, and networking sessions.
Register before July 29 to save USD100 on your registration.


Written by Richard Daverman, PhD.

Recent
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010

Click a link below to view the mailing archive as if it had been sent to you.

2022-06-28 01:30Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug and more...
2022-06-26 01:30Week in Review: invoX, a Sino Biopharm Company, to Pay $161 Million to Acquire F-Star
2022-06-25 01:30Reistone Completes $100 Million A Round for Inflammatory Disease Drugs and more...
2022-06-24 01:30Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million and more...
2022-06-23 01:30Xuanzhu Out-Licenses China Rights for Two Antibiotics in $66 Million Deal and more...
2022-06-22 01:30Beijing’s Therorna Raises $42 Million for circRNA Vaccines/Therapies (Including COVID) and more...
2022-06-21 01:30Shenzhen's AxBio Raises $100 Million for Low-Cost, High Precision Sequencing Machines
2022-06-19 01:30Week in Review: Joincare Plans $300-$400 Million IPO on Swiss Exchange
2022-06-18 01:30MegaRobo Raises $300 Million for Automated Drug Lab Systems and Robots and more...
2022-06-17 01:30Joincare Plans IPO on the SIX Swiss Stock Exchange and more...
2022-06-16 01:30I-Mab’s Partner MorphoSys Out-Licenses Ex-China Rights for Two Oncology Candidates to HIBio and more...
2022-06-15 01:30Kangpu Doses First Patient in Phase IIa Trial for Protein Degradation Therapy and more...
2022-06-14 01:30Organon Pays $103 Million to Acquire Global Rights for Two Henlius Biosimilars and more...
2022-06-12 01:30Week in Review: Fosun Pays $158 Million for Controlling Stake in Singapore Medical Centers
2022-06-11 01:30Everest Approved to Launch ADC for Triple-Negative Breast Cancer in China and more...
2022-06-10 01:30Shanghai Degron Raises $22 Million for Protein Degradation Drugs and more...
2022-06-09 01:30Fosun Acquires 60% Stake in Singapore Medical Center Chain for $158 Million and more...
2022-06-08 01:30CStone Reports PD-L1 Approved for Stage III NSCLC Following Chemoradiotherapy and more...
2022-06-07 01:30Insilico Medicine Completes $60 Million Funding; Will Build Robotic Drug Discovery Lab and more...
2022-06-05 01:30Week in Review: Vivo Raises $600 Million in First Tranche of China PE Fund
2022-06-04 01:30NuProbe Raises $50 Million for Genomics and Molecular Diagnostics and more...
2022-06-03 01:30ProfoundBio Closes $70 Million Series A+ Funding for ADC and Immunotherapy Drugs and more...
2022-06-02 01:30Vivo Capital Closes First Tranche of China Fund at $600 Million; Aiming for $1.5 Billion and more...
2022-06-01 01:30Hansoh Publishes Positive Results in ASCO Journal for Third-Gen EGFR-TKI Inhibitor and more...

Please enter all required fields Click to hide
Correct invalid entries Click to hide
 

Subscribe >>


Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC